Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment

@inproceedings{Alten2014LongTermSO,
  title={Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment},
  author={Rieke E Alten and Jeffrey L Kaine and Edward Keystone and Peter Nash and Ingrid Delaet and Mark C Genovese},
  booktitle={Arthritis & rheumatology},
  year={2014}
}
OBJECTIVE To investigate the safety of long-term subcutaneous (SC) abatacept treatment using integrated clinical trial data obtained in patients with rheumatoid arthritis refractory to traditional disease-modifying antirheumatic drugs. METHODS Data from the double-blind and open-label phases of 5 clinical trials of SC abatacept were pooled. The overall and 6-month incidence rates were calculated as events per 100 patient-years of exposure. RESULTS This analysis included 1,879 patients with… CONTINUE READING